Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track COGT with free AI briefings, catalyst countdowns, and dilution alerts.

COGT · Cogent Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$791.1M Cash on Hand
30mo Cash Runway
10.1% Short Interest
$55.82 Analyst Target (11)
Follow COGT by email Get an email when COGT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about COGT, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2026-11-30 bezuclastinib GIST NDA 66%
2026-12-30 bezuclastinib nonadvanced systemic mastocytosis NDA 66%
2027-06-29 bezuclastinib advanced systemic mastocytosis NDA 66%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What COGT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sunitinib Advanced Gastrointestinal Stromal Tumors Phase 3 · NCT05208047 Recruiting
Bezuclastinib (CGT9486) Advanced Gastrointestinal Stromal Tumors Phase 3 · NCT05208047 Recruiting
FGFR2/3 Inhibitor CGT4859 Intrahepatic Cholangiocarcinoma (Icc) Phase 1/2 · NCT06777316 Active not recruiting
Pexidartinib Gastrointestinal Stromal Tumors Phase 1/2 · NCT02401815 Completed
ACTR T Cell Product Solid Tumor Phase 1 · NCT03680560 Terminated
Anti-BCMA Antibody SEA-BCMA Multiple Myeloma Phase 1 · NCT03266692 Terminated
PI3Ka H1047R Mutant Selective Inhibitor CGT6297 PIK3CA Mutations Phase 1 · NCT07383506 Recruiting
HER2 Mutant-selective Inhibitor CGT4255 Advanced Solid Tumor, Adult Phase 1 · NCT07361562 Recruiting
Autologous ACTR-CD16-CD28-expressing… Lymphoma Phase 1 · NCT03189836 Terminated
Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced… Lymphoma Phase 1 · NCT02776813 Completed

Also used in these trials (approved or third-party drugs, not COGT's own candidates): Midazolam Hydrochloride, Trastuzumab, Rituximab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

COGT holds $791.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $79M/quarter from operations, an estimated runway of 30 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 37 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COGT files for a raise →

👥 Who Owns COGT

Insiders 4% Institutions (436 holders) 96% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR, LLC Institution (13F) 26,852,012 15.43% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 13,593,063 7.81% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 8,691,589 5.00% 2026-06-30
Vanguard Portfolio Management LLC Institution (13F) 8,131,026 4.67% 2026-09-30
State Street Corporation Institution (13F) 7,770,149 4.47% 2026-09-30
Janus Henderson Group Ltd. Institution (13F) 7,432,956 4.27% 2026-09-30
Deerfield Management Company, L.P Institution (13F) 5,957,000 3.42% 2026-09-30
Fairmount Funds Management LLC
Director · +39,414 options
Insider 5,503,418 3.16% 2026-03-31
Wellington Management Group, LLP Institution (13F) 4,677,224 2.69% 2026-09-30
Geode Capital Management, LLC Institution (13F) 4,477,194 2.57% 2026-09-30
Andrew R Robbins
President and CEO, Director · +2.26M options
Insider 657,503 0.38% 2026-05-19
Cole Pinnow
Chief Commercial Officer · +830,000 options
Insider 216,650 0.12% 2025-12-17

Share count 173,994,452 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-01
filed 2026-10-05
Ferrante Karen Jean
Option award (A) 759 – –
2026-08-27
filed 2026-08-31
Morris Arlene
Option exercise (M) 41,927 – –
2026-08-27
filed 2026-08-31
Morris Arlene
Option exercise (M) 41,927 $5.64 41,927
2026-08-27
filed 2026-08-31
Morris Arlene
Option exercise (M) 3,583 $2.52 45,510
2026-08-27
filed 2026-08-31
Morris Arlene
Sale (S) 3,161 $37.54 0

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full COGT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COGT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.